12,553 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 12,553 shares of the biotechnology company’s stock, valued at approximately $326,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in shares of Exelixis by 25.1% during the fourth quarter. Wellington Management Group LLP now owns 129,935 shares of the biotechnology company’s stock valued at $3,117,000 after buying an additional 26,049 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 728 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Exelixis by 10.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 69,641 shares of the biotechnology company’s stock worth $1,653,000 after acquiring an additional 6,490 shares during the period. First Trust Direct Indexing L.P. acquired a new stake in shares of Exelixis during the 1st quarter worth approximately $250,000. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Exelixis by 4.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 128,033 shares of the biotechnology company’s stock worth $3,038,000 after purchasing an additional 5,037 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Down 0.7 %

Exelixis stock opened at $28.11 on Friday. Exelixis, Inc. has a 12-month low of $19.12 and a 12-month high of $29.75. The stock has a market capitalization of $8.52 billion, a price-to-earnings ratio of 43.92, a P/E/G ratio of 0.54 and a beta of 0.54. The stock has a 50-day simple moving average of $26.58 and a 200 day simple moving average of $23.97.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The business had revenue of $637.18 million during the quarter, compared to analyst estimates of $468.21 million. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 1.59 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on EXEL shares. JMP Securities restated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday, October 11th. The Goldman Sachs Group upgraded shares of Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. Stifel Nicolaus increased their price target on shares of Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada lifted their price objective on Exelixis from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average price target of $29.57.

Insider Activity

In other Exelixis news, EVP Dana Aftab sold 95,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the sale, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Exelixis news, EVP Dana Aftab sold 95,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the transaction, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock valued at $8,640,129 over the last 90 days. 2.85% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.